United States · Investor

RA Capital Management

Last cheque observed Oct 2026; 394 cheques on record.

Deploying nowNew fund $122M, Jul 2025Private equity

SeedSeries ASeries BTherapeuticCgtDrugs

Deploying now
88%of best year117cheques in 12 months, 394 on record
Since the last cheque8days00hrs00min00sec
Median round$93MRounds led14 of 394Sole investor17 roundsExits5 from the portfolioMostly inUnited States, 84%
Pitch RA Capital Management

RA Capital Management highlights

  1. 01

    117 cheques in the last 12 months

  2. 02

    Mostly Series B and Series C: 54% of its rounds

  3. 03

    Sole investor in 17 rounds, median $21M

  4. 04

    5 exits from the portfolio

What they do

RA Capital founds, funds, and scales companies across healthcare and planetary health to build a healthier future for all.From their own website
Type
Private equity (from a list, unverified)
Cheque size
Up to $5.0M as they say
Stages
SeedSeries ASeries BGrowthPre-IPO
Sectors
TherapeuticCgtDrugs
Based in
Boston, United States
Cold pitches
Accepted

The record

Every round we can evidence, newest first394 appearances

  1. 2026

    98 rounds

  2. Oct
    Star TherapeuticsUS · Pulse 2.0$200MWith 10 others
  3. Oct
    Zai LabCN · Pulse 2.0$250MWith 10 others
  4. Oct
    OptivoltSeries A · US · Google News search$32MWith 6 others
  5. Sept
    Korsana BiosciencesUS$380MWith 3 others
  6. Sept
    AN2 TherapeuticsGrant · US$40MWith 4 others
  7. Sept
    Navigator MedicinesVenture · US$10MWith 1 other
  8. Sept
    Tyra BiosciencesUS$400MWith 5 others
  9. Sept
    Tectora TherapeuticsSeries A · US$55MWith 1 other
  10. Sept
    Helus PharmaCA$50MWith 3 others
  11. Sept
    Solstice OncologySeries A · US$225MWith 2 others
  12. Sept
    PlantedVenture · US$32MWith 2 others
  13. Sept
    Circle PharmaSeries E · US$93MWith 1 other
  14. Sept
    Superluminal MedicinesSeries B · US$66MWith 4 others
  15. Sept
    MMIVenture$20MWith 4 others
  16. Sept
    Pyxis OncologyUS$110MWith 4 others
  17. Sept
    Typewriter TherapeuticsSeries A · US$56MWith 1 other
  18. Aug
    Reframe SystemsUS · Ventureburn$40MWith 12 others
  19. Aug
    AusperBio TherapeuticsSeries C · US · TechStartups$120MWith 7 others
  20. Aug
    Expedition TherapeuticsSeries B · US$115MWith 3 others
  21. Jul
    Q32 BioUS$200MWith 2 others
  22. Jul
    Spero TherapeuticsDebt · US · HealthCare Royalty$105MWith 3 others
  23. Jul
    Commons ClinicVenture · US$10MWith 2 others
  24. Jul
    Alchemab TherapeuticsSeries A · GB$34MWith 4 others
  25. Jul
    Claris BiotherapeuticsSeries B · US$118MWith 4 others
  26. Jul
    FreenomeUS$240MWith 4 others
  27. Jul
    Dyne TherapeuticsUS$375MWith 3 others
  28. Jul
    Scribe TherapeuticsUS$7.5MWith 4 others
  29. Jun
    cAMPfield Therapeutics, Inc.Series A · US · Frazier Life Sciences$180MWith 7 others
  30. Jun
    SonoTheraSeries B · US · Ventureburn$125MWith 10 others
  31. Jun
    Element BiosciencesGrowth · US · Ventureburn$175MWith 4 others
  32. Jun
    ContralineSeries B · Ventureburn$93MLed
  33. Jun
    Aurinia PharmaceuticalsCA$3.1MWith 2 others
  34. Jun
    CervoMedUS$11MSole investor
  35. Jun
    Medicenna TherapeuticsCA$4.4MWith 1 other
  36. Jun
    Memento MedicinesSeries A · GB · Avego Management$93MWith 4 others
  37. Jun
    CelcuityDebt · US$500MWith 3 others
  38. Jun
    Ollin BiosciencesSeries B · US$330MWith 4 others
  39. Jun
    Mineralys TherapeuticsDebt · US$500MWith 5 others
  40. Jun
    Tango TherapeuticsUS$600MWith 2 others
  41. Jun
    Jade BiosciencesUS$150MWith 4 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration9 named

BOBrigid O'BrienExecutive OfficeriFiling they signed
CJChristopher James CaliriChief Information OfficeriForm ADV
EPEric Paul RoseChief Compliance OfficeriForm ADV
KTKyle TeameyExecutive OfficeriFiling they signed
MSMichael SaulnierChief Financial OfficeriForm ADV
P(Peter (nmn) KolchinskyDr. Kolchinsky is a Managing PartneriFiling they signed
RMRajeev Mahesh ShahMr. Shah is a Managing PartneriFiling they signed
RHRichard H. (mi Only) AldrichPartneriForm ADV
SWSarah Watt Burgess ReedGeneral CounseliForm ADV

We also hold 122 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$16Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
Legal name
RA Capital Management, LP
SEC number
CRD 160174

Funds on its Form ADV

5 private funds, $11B in gross assets · filed Mar 2024

Venture 4Hedge 1

  1. RA Capital Healthcare Fund, L.P.Hedge1,046 investors$9.4B
  2. RA Capital Nexus III Fund, L.P.Venture234 investors$1.0B
  3. RA Capital Nexus II Fund, L.P.Venture196 investors$430M
  4. RA Capital Nexus Fund, L.P.Venture95 investors$309M
  5. RA Capital Planetary Health Fund, L.P.Venture17 investors$62M

What they claim to have backed

From their own portfolio page (on their website)

0 of 2 we have independently watched raise

Gateway ↗ Board toolsRacap

Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.

Exits from the portfolio

Companies it backed that were later bought or listed5 in all

ZS PharmaBought by AstraZeneca$2.7BNov 2015
Civitas TherapeuticsBought by Acorda Therapeutics$525MSept 2014
Lumena PharmaceuticalsBought by Shire$260MMay 2014
bluebird bioListed$101MJun 2013

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as RA Capital Management. A count of rooms they were both in, not a relationship either has claimed.

Recently backed

The latest companies RA Capital Management put money into.

Quick answers about RA Capital Management

What does RA Capital Management invest in?

RA Capital Management invests most often at Series B and Series C (54% of the rounds on record), in sectors such as Therapeutic, Cgt and Drugs.

How active is RA Capital Management?

394 investments on record, 117 of them in the last 12 months, and it led 14. The most recent was in Oct 2026.

What has RA Capital Management invested in recently?

Its most recent investments on record: Star Therapeutics (Undisclosed round, Oct 2026), Zai Lab (Undisclosed round, Oct 2026) and Optivolt (Series A, Oct 2026).

How big are RA Capital Management's cheques?

The median round it joins is $93M.

Does RA Capital Management lead rounds?

Sometimes: it led 14 of its 394 investments on record (4%).

Where does RA Capital Management invest?

Most of the companies it backs are in the United States (84%), Canada (8%) and the United Kingdom (5%).

Is RA Capital Management investing now?

Yes: it is actively investing, with 117 investments in the last 12 months.

Who does RA Capital Management invest alongside?

Most often Janus Henderson Investors (68 rounds together), OrbiMed (52 rounds together) and Cormorant Asset Management (45 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it